Editorial: Treatment of herpesvirus infections.
D000998:Antiviral Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000627:therapeutic use; D004254:DNA Nucleotidyltransferases / Q000037:antagonists & inhibitors; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D010919:Placebos; D011684:Purine Nucleosides / Q000627:therapeutic use*; D012008:Recurrence; D014740:Vidarabine / Q000627:therapeutic use*
D000998:Antiviral Agents; D010919:Placebos; D011684:Purine Nucleosides; D003561:Cytarabine; D004254:DNA Nucleotidyltransferases; D014740:Vidarabine; D007065:Idoxuridine